Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer

• Published in: Cancer immunology research 2022-01, Vol.10 (1), p.126-141
• Main Authors: Celus, Ward, Oliveira, Ana I, Rivis, Silvia, Van Acker, Heleen H, Landeloos, Ewout, Serneels, Jens, Cafarello, Sarah Trusso, Van Herck, Yannick, Mastrantonio, Roberta, Köhler, Arnaud, Garg, Abhishek D, Flamand, Véronique, Tamagnone, Luca, Marine, Jean-Christophe, Di Matteo, Mario, Costa, Bruno M, Bechter, Oliver, Mazzone, Massimiliano
• Format: Article
• Language: English
• Subjects: Animals; CD8-Positive T-Lymphocytes - immunology; Cell Line, Tumor; Humans; Immunotherapy - methods; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Lymphocyte Activation; Melanoma, Experimental - immunology; Melanoma, Experimental - pathology; Melanoma, Experimental - therapy; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - pharmacology; Programmed Cell Death 1 Receptor - immunology; Receptors, Cell Surface - genetics; T-Lymphocytes, Cytotoxic - immunology; Tumor Microenvironment - immunology
• ISSN: 2326-6066; 2326-6074
• DOI: 10.1158/2326-6066.CIR-21-0061

Cytotoxic T cell (CTL) infiltration of the tumor carries the potential to limit cancer progression, but their exclusion by the immunosuppressive tumor microenvironment hampers the efficiency of immunotherapy. Here, we show that expression of the axon guidance molecule Plexin-A4 ( ) in CTLs, especially in effector/memory CD8 T cells, is induced upon T-cell activation, sustained in the circulation, but reduced when entering the tumor bed. Therefore, we deleted and observed that -deficient CTLs acquired improved homing capacity to the lymph nodes and to the tumor, as well as increased proliferation, both achieved through enhanced Rac1 activation. Mice with stromal or hematopoietic deletion exhibited enhanced CTL infiltration and impaired tumor growth. In a melanoma model, adoptive transfer of CTLs lacking prolonged survival and improved therapeutic outcome, which was even stronger when combined with anti-programmed cell death protein 1 (PD-1) treatment. abundance in circulating CTLs was augmented in melanoma patients versus healthy volunteers but decreased after the first cycle of anti-PD-1, alone or in combination with anti-cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), in those patients showing complete or partial response to the treatment. Altogether, our data suggest that Plxna4 acts as a "checkpoint," negatively regulating CTL migration and proliferation through cell-autonomous mechanisms independent of the interaction with host-derived Plxna4 ligands, semaphorins. These findings pave the way toward Plxna4-centric immunotherapies and propose Plxna4 detection in circulating CTLs as a potential way to monitor the response to immune checkpoint blockade in patients with metastatic melanoma.